Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Neoadjuvant hyperfractionated-accelerated radiotherapy with concomitant chemotherapy in esophageal cancer: phase II study.

Saglam S, Arifoglu A, Saglam EK, Tunca F, Asoglu O, Engin G, Yamaner S.

J Gastrointest Oncol. 2013 Dec;4(4):380-7. doi: 10.3978/j.issn.2078-6891.2013.022.

2.
3.

Preoperative low-dose weekly cisplatin and continuous infusion fluorouracil plus hyperfractionated radiotherapy in stage II-III esophageal carcinoma.

Caro M, Font A, Comas S, Viciano M, Remon J, Céliz P, Robles J, Musulén E, Sendrós MJ, Mesalles E, Jiménez JA, Boix J, Arellano A, Fernández-Llamazares J.

Clin Transl Oncol. 2016 Nov;18(11):1106-1113. Epub 2016 Feb 8.

PMID:
26856597
4.

Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).

Tsuchiya S, Ohe Y, Sugiura T, Fuwa N, Kitamoto Y, Mori K, Kobayashi H, Nakata K, Sawa T, Hirai K, Etoh T, Saka H, Saito A, Fukuda H, Ishizuka N, Saijo N; Japan Clinical Oncology Group Study.

Jpn J Clin Oncol. 2001 Oct;31(10):488-94.

PMID:
11696618
5.
6.

Dose escalation using twice-daily radiotherapy for nasopharyngeal carcinoma: does heavier dosing result in a happier ending?

Jen YM, Lin YS, Su WF, Hsu WL, Hwang JM, Chao HL, Liu DW, Chen CM, Lin HY, Wu CJ, Chang LP, Shueng PW.

Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):14-22.

PMID:
12182970
7.

Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.

Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M; Study Group for Therapies of Rectal Malignancies (STORM).

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. Epub 2006 Jan 18.

PMID:
16414206
8.

A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.

Vokes EE, Haraf DJ, Drinkard LC, Hoffman PC, Ferguson MK, Vogelzang NJ, Watson S, Lane NJ, Golomb HM.

Cancer Chemother Pharmacol. 1995;35(4):304-12.

PMID:
7530173
9.
10.
11.

There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy.

Mandell LR, Kadota R, Freeman C, Douglass EC, Fontanesi J, Cohen ME, Kovnar E, Burger P, Sanford RA, Kepner J, Friedman H, Kun LE.

Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):959-64.

PMID:
10192340
12.

Neoadjuvant short-course hyperfractionated accelerated radiotherapy (SC-HART) combined with S-1 for locally advanced rectal cancer.

Doi H, Beppu N, Odawara S, Tanooka M, Takada Y, Niwa Y, Fujiwara M, Kimura F, Yanagi H, Yamanaka N, Kamikonya N, Hirota S.

J Radiat Res. 2013 Nov 1;54(6):1118-24. doi: 10.1093/jrr/rrt058. Epub 2013 May 8. Erratum in: J Radiat Res. 2014 Nov;55(6):1202.

13.
14.

Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.

Kuhnt T, Becker A, Pigorsch S, Pelz T, Bloching M, Passmann M, Lotterer E, Hänsgen G, Dunst J.

Strahlenther Onkol. 2003 Oct;179(10):673-81.

PMID:
14566475
15.

High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results.

King SC, Acker JC, Kussin PS, Marks LB, Weeks KJ, Leopold KA.

Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):593-9.

PMID:
8948343
16.

Late course accelerated hyperfractionated radiotherapy plus concurrent chemotherapy for squamous cell carcinoma of the esophagus: a phase III randomized study.

Zhao KL, Shi XH, Jiang GL, Yao WQ, Guo XM, Wu GD, Zhu LX.

Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1014-20.

PMID:
15990003
17.

Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.

Ma HB, Di ZL, Wen J, Ke Y, Sun X, Ren J.

Jpn J Clin Oncol. 2015 Feb;45(2):169-75. doi: 10.1093/jjco/hyu181. Epub 2014 Nov 21.

PMID:
25416813
18.
19.

Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.

Murakami M, Kuroda Y, Okamoto Y, Kono K, Yoden E, Kusumi F, Hajiro K, Matsusue S, Takeda H.

Int J Radiat Oncol Biol Phys. 1998 Mar 15;40(5):1049-59.

PMID:
9539559
20.

Concomitant chemotherapy and external radiotherapy plus brachytherapy for locally advanced esophageal cancer: results of a retrospective multicenter study.

Tessa M, Rotta P, Ragona R, Sola B, Grassini M, Nassisi D, Sciacero P, Airoldi M, Filippi A, Gianello L, De Angelis C, Ozzello F, Trotti AB, Ricardi U, Sannazzari GL.

Tumori. 2005 Sep-Oct;91(5):406-14.

PMID:
16459637

Supplemental Content

Support Center